Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 5:03 AM ET

Healthcare Equipment and Supplies

Company Overview of Cordis Corporation

Company Overview

Cordis Corporation, through its subsidiaries, develops, manufactures, and distributes drug-eluting stents, catheters, and guide wires for interventional medicine, minimally invasive computer-based imaging, and electrophysiology applications. The company offers a portfolio of access, diagnostic, and interventional medical products for use in cardiovascular, endovascular, and biliary duct (liver) obstructive interventional procedures. Its cardiology products include transradial solutions for radial access procedures; diagnostic products, such as access kits, sheath introducers, diagnostic guide wires, and diagnostic catheters; guiding and PTCA dilatation catheters; and steerable guide wires an...

6500 Paseo Padre Parkway

Fremont, CA 94555

United States

Founded in 1959

3,620 Employees



Key Executives for Cordis Corporation

Vice President of Worldwide Clinical Research & Operations
Chief Scientific Officer and Global Head of Research & Development
Age: 54
Vice President of Regulatory Affairs and Quality Assurance
Age: 67
Vice President of Latin American Operations
Age: 86
Vice President of Corporate Relations and Assistant Secretary
Age: 78
Compensation as of Fiscal Year 2015.

Cordis Corporation Key Developments

Wi-Lan Inc. Enters into Settlement, License Agreement with Codman & Shurtleff, Cordis Corporation

Wi-Lan (WILN) announced that it has entered into a settlement and license agreement with Codman & Shurtleff, Inc. and Cordis Corporation resolving the patent litigation that was pending in the United States District Court for the Central District of California.

Back Bay Medical Inc., Enters into Settlement and License Agreement with Codman & Shurtleff, Inc. and Cordis Corporation

WiLAN announced that the company's subsidiary, Back Bay Medical Inc., has entered into a settlement and license agreement with Codman & Shurtleff, Inc. and Cordis Corporation. The agreement resolves litigation that was pending in the United States District Court for the Central District of California.

Cordis Corporation Announces Launch of New ELITECROSS Support Catheter and OUTBACK Elite Re-Entry Catheter

Cordis Corporation announced launch of the new ELITECROSS Support Catheter in the United States and OUTBACK Elite Re-Entry Catheter in the United States, Europe and Japan. This expansion of the CORDIS Crossing Portfolio for treatment of chronic total occlusions (CTO) further underlines the company's decade-long commitment to the space. The new products will add to a suite of specialty and workhorse solutions designed to support physicians in crossing the most complex lesions with control and confidence. A chronic total occlusion (CTO) occurs when the accumulation of plaque becomes so severe that it results in a complete (or nearly complete) blockage of the vessel. When this occurs, physicians must find a way to cross the occlusion in order to complete treatment of the lesion using interventional techniques. The CORDIS Crossing Portfolio reduces the complexity of challenging cases and provides a comprehensive crossing solution of specialty and workhorse devices. The new ELITECROSS Support Catheter family provides unparalleled support and pushability to help get to and through complex lesions. The catheter features a braided shaft, tapered tip, lubricious hydrophilic coating and ultra low-friction inner lumen to enhance trackability over the guidewire. The ELITECROSS Support Catheter is designed to provide additional support to the distal portion of diagnostic or interventional devices, and is compatible with the FRONTRUNNER® XP CTO Catheter as well as other ancillary devices. The redesigned OUTBACK Elite Re-Entry Catheter enables faster and more precise re-entry into the true lumen in the most challenging cases, and represents the first ever re-entry device available in Japan. With a focus on control and precision, the OUTBACK Elite Catheter was redesigned with an ergonomic handle and torque control location enabling single-handed operation by the user. The addition of an 80 cm shaft length will aid in optimizing procedures by reducing the length of shaft outside the patient. These new features combined with a redesigned package make the OUTBACK Elite Re-Entry Catheter a more convenient, precision re-entry tool for the toughest lesions of peripheral vascular disease. In a recent study by Gandini et al., the OUTBACK Re-Entry Catheter was shown to have a higher success rate of precision re-entry versus manual wire techniques.

Similar Private Companies By Industry

Company Name Region
Precision Micro Devices, LLC United States
Advanced Monitors Corporation United States
NTERO Surgical, Inc. United States
AmniSure International LLC United States
Syneron Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cordis Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at